Greg Tyler

[NOTRELOAD AI @notreload_ai]

$COYA gets Buy rating; ALS drug COYA 302 shows early promise, could double stock if trials succeed, high risk biotech. https://t.co/orxFXJFcFQ

[Coya Therapeutics @CoyaTx]

Our Senior Director of Clinical Development, Tyrell Simkins, D.O., Ph.D., will present the poster, “ALSTARS: A Precision Immunomodulatory Phase 2 Trial of COYA 302 Targeting Regulatory T Cells and Neuroinflammation in ALS,” on Wednesday, June 3 at 4:45 PM ET at the 5th ALS Drug Development Summit.

For more information: https://t.co/nDJ1miXHxt

[Greg Tyler @oldguy999]

@WorkElizab 15

[Ozmosi @OzmosiHealth]

$COYA Coya Therapeutics announced they will present P2 Amyotrophic Lateral Sclerosis results on 2026-06-03 for COYA-302

More Info: https://t.co/53XthtXVQX

[Healio Neurology @healioneurology]

Patients with #ALS treated with Coya 302 saw increases in regulatory T cells, less #inflammation and slower disease progression, said Dr. Fred Grossman, president of @CoyaTx.

https://t.co/amwPJrvYWe

[ALS News Today @alsnewstoday]

Coya Therapeutics’ experimental injection therapy COYA 302 has been granted fast track designation by the U.S. FDA for treating ALS.  https://t.co/Lb08LaepZN

#ALS #ALSNewsToday #Bionews #ALSCommunity

[Coya Therapeutics @CoyaTx]

Coya is pleased to announce that the FDA has granted Fast Track Designation to COYA 302 for the treatment of #ALS.

Fast Track Designation is intended to facilitate the development and expedite the review of therapies for serious conditions with significant unmet medical need. This designation underscores the urgent need for new treatment options for people living with ALS and supports the continued advancement of COYA 302 through the regulatory process.

For more details: https://t.co/MoSGPIvij4

$COYA

[Greg Tyler @oldguy999]

@Jennnyyyyyy 7 *4. =28.

Plus 9. Is 37

[Greg Tyler @oldguy999]

@otokyo I am pregnant

[Ozmosi @OzmosiHealth]

$COYA +nan% today

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

More Info: https://t.co/53XthtXVQX

[Market Wire News @marketwirenews]

$COYA - Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

News & Disclaimer
https://t.co/n5e27W6kxX

[utex.io @UTEX_io]

$COYA — Coya Therapeutics' stock has risen following the company's disclosure of a study showing that COYA 302 elevated three specific biomarkers in individuals with ALS, contrasting with control subjects.

[Greg Tyler @oldguy999]

@alifarhat79 Total due says 99.10. So paying 14.87 instead of that would be a bargain

[Greg Tyler @oldguy999]

@BeckyQuick @Kramer_Katie Hereditary gene mutations is something that has affected my family. Thankfully it’s not common I would not wish it on anyone. Knowing my kids could get this stinks

[Coya Therapeutics @CoyaTx]

Coya today announced the acceptance of the clinical trial application from Health Canada to proceed with the COYA 302 ALSTARS trial for #ALS. This allows for initiation of patient enrollment in the ALSTARS Trial at Canadian ALS centers.

For more details: https://t.co/N5ZZaBvkGN

[Greg Tyler @oldguy999]

@RightPulseNewss He’ll no

[Greg Tyler @oldguy999]

@AntiLeftMemes flip Wilson

[Greg Tyler @oldguy999]

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS - https://t.co/BFyAZDq7YN

[US Homeland Security News @defense_civil25]

🚨Update: UN staff in New York sabotage escalators at UN building. Also sabotaged Trump’s teleprompter in an attempt to embarrass him.

[PRISM MarketView @PrismMarketView]

(NASDAQ: $COYA)
Coya Therapeutics has launched the ALSTARS Phase 2 trial of COYA 302 in ALS. The 120-patient study will assess safety and efficacy across 25 sites in the U.S. and Canada, with a blinded extension to evaluate long-term outcomes. A key step toward addressing one of the toughest unmet needs in neurodegeneration.
@CoyaTx
https://t.co/NoBg4iPKGh